Hubungan Faktor Risiko dengan Penggunaan Obat pada Pasien Sindrom Ovarium Polikistik di Klinik Kencana, Kota Sorong
Bilah Samping Artikel
Isi Artikel Utama
Page: 2801-2807
Abstrak
Sindrom ovarium polikistik (polycystic ovary syndrome/PCOS) memerlukan farmakoterapi individual karena manifestasi reproduktif dan metaboliknya bervariasi antarpasien. Penelitian ini mengevaluasi hubungan usia, keluhan menstruasi yang terdokumentasi, dan presentasi terkait kehamilan dengan kategori jumlah obat pada pasien PCOS di Klinik Kencana, Kota Sorong. Analisis potong lintang retrospektif dilakukan terhadap 118 rekam medis yang dipilih melalui simple random sampling berbasis bilangan acak komputer dari 412 rekam medis periode Januari 2022-Desember 2023. Hubungan dianalisis menggunakan uji chi-square dan dinyatakan sebagai odds ratio (OR) dengan interval kepercayaan (CI) 95%. Pasien berusia >25 tahun lebih berpeluang menerima >2 obat dibandingkan pasien berusia ≤25 tahun (40/73 dibandingkan 16/45; OR = 2,197; 95% CI = 1,022-4,721; p = 0,042). Keluhan menstruasi dan presentasi terkait kehamilan tidak berhubungan signifikan dengan kategori jumlah obat (masing-masing p = 0,297). Usia yang lebih tua berhubungan dengan kompleksitas jumlah obat yang lebih tinggi, tetapi tidak membuktikan kausalitas. Perencanaan terapi perlu mengintegrasikan usia, status metabolik, komorbiditas, dan tujuan reproduksi.
Unduhan
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Referensi
Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12(4):1454. doi:10.3390/jcm12041454. DOI: https://doi.org/10.3390/jcm12041454
Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1303-1314. doi:10.1007/s00404-024-07607-x. DOI: https://doi.org/10.1007/s00404-024-07607-x
Christie, Halimah E, Yohanes DC. Review artikel: Pengaruh metformin sebagai obat off-label untuk terapi pada wanita dengan polycystic ovary syndrome (PCOS). Farmaka. 2023;21:64-77.
Kesavan S, Chaudhry GS, Akim AM, Ranneh YK. The efficacy of metformin and exenatide in polycystic ovary syndrome (PCOS) patients. Ars Pharm. 2023;64(2):100-122. doi:10.30827/ars.v64i2.27302. DOI: https://doi.org/10.30827/ars.v64i2.27302
Yu JH, Moon MK, Ahn HC, Yang YM. Assessing medication use patterns among patients with polycystic ovary syndrome at a tertiary care teaching hospital in South Korea: a retrospective study. Medicine (Baltimore). 2024;103(32):e39055. doi:10.1097/MD.0000000000039055. DOI: https://doi.org/10.1097/MD.0000000000039055
World Health Organization. Polycystic ovary syndrome [Internet]. Geneva: World Health Organization; 2023 [cited 2026 Aug 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome.
Zeng LH, Rana S, Hussain L, Asif M, Mehmood MH, Imran I, et al. Polycystic ovary syndrome: a disorder of reproductive age, its pathogenesis, and a discussion on the emerging role of herbal remedies. Front Pharmacol. 2022;13:874914. doi:10.3389/fphar.2022.874914. DOI: https://doi.org/10.3389/fphar.2022.874914
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24. doi:10.1093/humrep/der396. DOI: https://doi.org/10.1093/humrep/der396
Dason ES, Koshkina O, Chan C, Sobel M. Diagnosis and management of polycystic ovarian syndrome. CMAJ. 2024;196(3):E85-E94. doi:10.1503/cmaj.231251. DOI: https://doi.org/10.1503/cmaj.231251
Legro R. Diagnosis and treatment of polycystic ovary syndrome (PCOS): an interview with Richard Legro. BMC Med. 2015;13:64. doi:10.1186/s12916-015-0299-2. DOI: https://doi.org/10.1186/s12916-015-0299-2
Ratnaningsih D, Siswatibudi H, Yogi Hernawan J. Gambaran terapi penggunaan obat pada wanita usia subur dengan masalah reproduksi PCOS (polycystic ovarian syndrome) di Yogyakarta. J Permata Indones. 2022;13(2):136-144. doi:10.59737/jpi.v13i2.172. DOI: https://doi.org/10.59737/jpi.v13i2.172
Kujanpää L, Arffman RK, Pesonen P, Hurskainen E, Järvelin MR, Franks S, et al. Polycystic ovary syndrome presents as a multimorbid condition by age 50: birth cohort linkage to national register data. Eur J Endocrinol. 2024;190(6):409-420. doi:10.1093/ejendo/lvae057. DOI: https://doi.org/10.1093/ejendo/lvae057
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran LJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618. doi:10.1093/humrep/dey256. DOI: https://doi.org/10.1093/humrep/dey256
Dokras A, Saini S, Gibson-Helm M, Schulkin J, Cooney LG, Teede HJ. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome. Fertil Steril. 2017;107(6):1380-1386.e1. doi:10.1016/j.fertnstert.2017.04.011. DOI: https://doi.org/10.1016/j.fertnstert.2017.04.011
Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics. 2015;70(11):765-769. doi:10.6061/clinics/2015(11)09. DOI: https://doi.org/10.6061/clinics/2015(11)09
Peng G, Yan Z, Liu Y, Li J, Ma J, Tong N, et al. The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. Reprod Biol Endocrinol. 2023;21(1):24. doi:10.1186/s12958-023-01075-9. DOI: https://doi.org/10.1186/s12958-023-01075-9
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767-793. doi:10.1016/j.fertnstert.2023.07.025. DOI: https://doi.org/10.1016/j.fertnstert.2023.07.025
Strauss JF, Barbieri RL, Dokras A, Williams CJ, Williams SZ, editors. Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management [Internet]. 9th ed. Philadelphia: Elsevier; 2023 [cited 2026 Aug 27]. Available from: ClinicalKey, https://www.clinicalkey.com.
Ee C, Tay CT. Pharmacological management of polycystic ovary syndrome. Aust Prescr. 2024;47(4):109-112. doi:10.18773/AUSTPRESCR.2024.030. DOI: https://doi.org/10.18773/austprescr.2024.030
Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer PM, et al. Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109(2):e817-e836. doi:10.1210/clinem/dgad465. DOI: https://doi.org/10.1210/clinem/dgad465
Alesi S, Forslund M, Melin J, Romualdi D, Peña A, Tay CT, et al. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2023;63:102162. doi:10.1016/j.eclinm.2023.102162. DOI: https://doi.org/10.1016/j.eclinm.2023.102162
Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(5):e13704. doi:10.1111/obr.13704. DOI: https://doi.org/10.1111/obr.13704
Forslund M, Melin J, Stener-Victorin E, Teede H, Vanky E, Piltonen T. International evidence-based guideline on assessment and management of PCOS: a Nordic perspective. Acta Obstet Gynecol Scand. 2024;103(1):7-12. doi:10.1111/aogs.14725. DOI: https://doi.org/10.1111/aogs.14725